# Novel Nanoparticle-in-Hydrogel Co-delivery of Adjuvanted saRNA as HIV Vaccine

> **NIH NIH N43** · ZYMERON CORPORATION · 2020 · $300,000

## Abstract

Particle-Based Co-Delivery of HIV Immunogens as Next-Generation HIV Vaccines: A major focus of HIV vaccine research has been the development of immunogens that elicit broadly neutralizing antibody responses targeting the envelope protein (Env). While the field has predominantly focused on immunogen design and soluble antigens, the targeted and controlled delivery of antigens has not received much attention and is a gap in the HIV field that needs to be addressed. Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, selfamplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies.

## Key facts

- **NIH application ID:** 10215313
- **Project number:** 75N93020C00011-0-9999-1
- **Recipient organization:** ZYMERON CORPORATION
- **Principal Investigator:** FANG LIU
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $300,000
- **Award type:** —
- **Project period:** 2020-06-01 → 2021-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10215313

## Citation

> US National Institutes of Health, RePORTER application 10215313, Novel Nanoparticle-in-Hydrogel Co-delivery of Adjuvanted saRNA as HIV Vaccine (75N93020C00011-0-9999-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10215313. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*